Beyond blood transfusions: exploring iron chelation therapies in transfusion-dependent beta-thalassemia

被引:0
作者
Talha, Muhammad [1 ]
Ali, Mohammad Haris [1 ]
Hurjkaliani, Sonia [2 ]
Rahmat, Zainab Syyeda [2 ]
Sadia, Haleema [3 ]
Al Hasibuzzaman, Md. [4 ]
Uzair, Ahsan Ul Qayyum [1 ]
机构
[1] Shaikh Khalifa Bin Zayed Al Nahyan Med & Dent Coll, Dept Pediat, Lahore, Pakistan
[2] Dow Univ Hlth Sci, Dept Pediat, Karachi, Pakistan
[3] Karachi Inst Med Sci, Dept Pediat, Karachi, Pakistan
[4] Univ Dhaka, Inst Nutr & Food Sci, Suhrawardi Udyan Rd, Dhaka 1000, Bangladesh
关键词
children; deferiprone; FDA-approved; infants; transfusion-induced beta-thalassemia (TBT); DEFERIPRONE; DEFERASIROX; EFFICACY; SAFETY;
D O I
10.1097/MS9.0000000000002796
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction:Abnormal hemoglobin, or hemoglobinopathy, affects about 7% of the global population. Major hemoglobinopathies like beta-thalassemia and sickle cell disease require regular blood transfusions, leading to chronic iron overload. This review examines the efficacy and safety of deferiprone, an oral iron chelator, in managing iron overload in pediatric patients with transfusion-dependent conditions.Methods:Data were sourced from PubMed, Google Scholar, and relevant articles, focusing on randomized controlled trials (RCTs) published between 2010 and 2023. The search terms included "deferiprone," "iron chelation," "transfusion," "iron overload," "hemoglobinopathies," and "thalassemia." Three RCTs met the inclusion criteria, involving 521 pediatric patients.Results:The START trial demonstrated that early-start deferiprone significantly reduced iron load compared to placebo, with no severe adverse events. The DEEP-2 study found deferiprone non-inferior to deferasirox in terms of efficacy and safety. Another trial highlighted the benefits of early deferiprone therapy in delaying iron overload symptoms without serious side effects. Common adverse effects included pyrexia, nasopharyngitis, and decreased neutrophil count, but no significant differences in growth parameters, creatinine, or prolactin levels were observed.Conclusion:Deferiprone shows significant promise in managing iron overload in pediatric patients, with comparable effectiveness to existing therapies and a favorable safety profile. Its oral administration is advantageous for young children. However, long-term studies are needed to fully understand its safety and efficacy. Addressing challenges such as patient compliance and adverse effects through education, personalized medicine, and advanced monitoring techniques can further improve treatment outcomes for beta-thalassemia patients.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 50 条
[41]   Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia – A Prospective Observational Study [J].
Rajeswari Rethinaswamy DivakarJose ;
C. G. Delhikumar ;
G. Ram Kumar .
Indian Journal of Pediatrics, 2021, 88 :330-335
[42]   Iron-Chelating Therapies in a Transfusion-Dependent Thalassaemia Population in ThailandA Cost-Effectiveness Study [J].
Nantasit Luangasanatip ;
Nathorn Chaiyakunapruk ;
Nilawan Upakdee ;
Peerapon Wong .
Clinical Drug Investigation, 2011, 31 :493-505
[43]   Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias [J].
Ho, P. J. ;
Tay, L. ;
Lindeman, R. ;
Catley, L. ;
Bowden, D. K. .
INTERNAL MEDICINE JOURNAL, 2011, 41 (07) :516-524
[44]   A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan [J].
Ho, Wan-Ling ;
Chung, Kuo-Piao ;
Yang, Szu-Sheng ;
Lu, Meng-Yao ;
Jou, Shiann-Tarng ;
Chang, Hsiu-Hao ;
Yang, Yung-Li ;
Lin, Dong-Tsamn ;
Lin, Kai-Hsin .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2013, 112 (04) :221-229
[45]   The long-term efficacy in blood transfusions, hematologic parameter changes, and complications after splenectomy in patients with transfusion-dependent thalassemia [J].
Osataphan, Nichanan ;
Dumnil, Somying ;
Tantiworawit, Adisak ;
Punnachet, Teerachat ;
Hantrakun, Nonthakorn ;
Piriyakhuntorn, Pokpong ;
Rattanathammethee, Thanawat ;
Hantrakool, Sasinee ;
Chai-Adisaksopha, Chatree ;
Rattarittamrong, Ekarat ;
Norasetthada, Lalita ;
Fanhchaksai, Kanda ;
Charoenkwan, Pimlak .
TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (03)
[46]   Pulmonary function in patients with transfusion-dependent thalassemia and its associations with iron overload [J].
Chan, Kate C. ;
Au, Chun T. ;
Leung, Alex W. K. ;
Li, Albert M. ;
Li, Chi-kong ;
Wong, Matthew M. T. ;
Li, Carol S. T. ;
Cheung, Hang L. ;
Fan, Philip ;
Ling, Siu C. ;
Li, Rever C. H. ;
Ha, S. Y. .
SCIENTIFIC REPORTS, 2023, 13 (01)
[47]   Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia [J].
Mohamed, Rafaa ;
Abdul Rahman, Amir Hamzah ;
Masra, Farin ;
Abdul Latiff, Zarina .
FRONTIERS IN PEDIATRICS, 2022, 10
[48]   MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox [J].
Antonella Meloni ;
Mari Giovanna Neri ;
Maria Chiara Resta ;
Massimiliano Missere ;
Antonino Vallone ;
Vincenzo Positano ;
Silvia Macchi ;
Crocetta Argento ;
Daniele De Marchi ;
Alessia Pepe .
Journal of Cardiovascular Magnetic Resonance, 17 (Suppl 1)
[49]   Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias [J].
Hanneman, Kate ;
Raju, Vikram M. ;
Moshonov, Hadas ;
Ward, Richard ;
Wintersperger, Bernd J. ;
Crean, Andrew M. ;
Ross, Heather ;
Nguyen, Elsie T. .
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2013, 29 (07) :1517-1526
[50]   Efficacy and Safety of a Dispersible Tablet of GPO-Deferasirox Monotherapy among Children with Transfusion-Dependent Thalassemia and Iron Overload [J].
Chuansumrit, Ampaiwan ;
Songdej, Duantida ;
Sirachainan, Nongnuch ;
Kadegasem, Praguywan ;
Saisawat, Pawaree ;
Sungkarat, Witaya ;
Kempka, Ketsuda ;
Tungbubpha, Noppawan .
HEMOGLOBIN, 2024, 48 (01) :47-55